Impact of RAGE polymorphisms on urothelial cell carcinoma clinicopathologic characteristics and long-term survival
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (9) , 573.e9-573.e17
Abstract
No abstract availableKeywords
Funding Information
- Chung Shan Medical University Hospital (CSH-2018-E-001-Y2)
This publication has 40 references indexed in Scilit:
- AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathwayAutophagy, 2012
- RAGE and cardiovascular diseaseFrontiers in Bioscience-Landmark, 2011
- Soluble form of a receptor for advanced glycation end products sRAGE as a biomarkerFrontiers in Bioscience-Elite, 2010
- The receptor RAGE: Bridging inflammation and cancerCell Communication and Signaling, 2009
- RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and InflammationJournal of Translational Medicine, 2009
- The receptor for advanced glycation endproducts (RAGE) and cardiovascular diseaseExpert Reviews in Molecular Medicine, 2009
- Bladder cancer SNP panel predicts susceptibility and survivalHuman Genetics, 2009
- Gly82Ser Polymorphism of the Receptor for Advanced Glycation End Products Is Associated with an Increased Risk of Gastric Cancer in a Chinese PopulationClinical Cancer Research, 2008
- Receptor for Advanced Glycation End Products (RAGE)—Soluble Form (sRAGE) and Gene Polymorphisms in Patients with Breast CancerCancer Investigation, 2007
- Expression of Receptors for Advanced Glycosylation End Products on Renal Cell Carcinoma Cells in VitroBiochemical and Biophysical Research Communications, 1993